Aileron Therapeutics (NASDAQ: ALRN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.090 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aileron Therapeutics (NASDAQ: ALRN) through any online brokerage.
Other companies in Aileron Therapeutics’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Virios Therapeutics (NASDAQ:VIRI), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX) and Celyad Oncology (NASDAQ:CYAD).
The latest price target for Aileron Therapeutics (NASDAQ: ALRN) was reported by HC Wainwright & Co. on Friday, June 5, 2020. The analyst firm set a price target for 2.00 expecting ALRN to rise to within 12 months (a possible 403.91% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Aileron Therapeutics (NASDAQ: ALRN) is $0.3969 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Aileron Therapeutics.
Aileron Therapeutics’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Aileron Therapeutics.
Aileron Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.